BEXMAB study Update
Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Inside Information: Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update · Three of five patients in the 6 mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR and mCR) · Eight of 15 objective responses observed in all three doublet dosing cohorts · One patient has stayed on treatment for 13 months · Updated BEXMAB data supports advancement to Phase II in H2 2023 focusing on SoC relapsed/